What is the potential impact of reduced DTG pricing?
WHO released a new publication in July 2017 advising countries on how to transition to DTG-based regimens. This transition of first-line treatment to DTG-based regimens is supported by WHO in an effort to prevent the spread of HIV drug resistance (HIVDR) and to improve viral suppression and quality of life for people living with HIV.
WHO believes that this new agreement to provide an affordable fixed-dose combination of TDF + 3TC + DTG (TLD) will enable more people to access improved and affordable HIV medicine, and that this agreement is consistent with WHO recommendations. WHO congratulates the governments of Kenya and South Africa, the Clinton Health Access Initiative and others on this landmark agreement. WHO will continue working with partners and countries to provide guidance on the safe introduction and monitoring of this important new class of ARVs.